SEC Form 4Coverage since Aug 27, 2025Open-market trades only
$VRTX insider trading
Over the last 12 months, Vertex Pharmaceuticals Inc / Ma insiders reported no purchases and 54 sales totaling $154.6M across SEC Form 4 filings. 93% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $154.6M 54 events
- Events · 12m
- 54 Form 4 filings, grouped
- Insiders · 12m
- 17 distinct reporters
- 10b5-1 share
- 93% of events, not dollars
Side
Price · $VRTX · 3Mvia TradingView
Top insiders · 12m
Bozic CarmenEVP and CMO8× · $7.6M
Tatsis OuraniaEVP, Chief Reg. & Quality Off.7× · $6.5M
Biller JonathanEVP and Chief Legal Officer6× · $4.1M
Liu JoyEVP and Chief Legal Officer5× · $2.1M
Ambrose KristenSVP & Chief Accounting Officer4× · $2.0M
All insider trades
50 of 55 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 1,500 | $524.99 | $787K | -3.2% | plan |
| Jul 2, 2026 | McKechnie DuncanEVP, Chief Commercial Officer · O | ▼ Sale | 1,541 | $519 | $800K | -12.3% | plan |
| Jul 1, 2026 | Liu JoyEVP and Chief Legal Officer · O | ▼ Sale | 828 | $502.71 | $416K | -4.1% | plan |
| Jun 26, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 596 | $482.5 | $288K | -3.7% | plan |
| Jun 18, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 1,020 | $462.17 | $471K | -6% | plan |
| Jun 15, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 4,062 | $450 | $1.8M | -19.3% | plan |
| Jun 5, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 1,745 | $450 | $785K | -7.7% | plan |
| Jun 1, 2026 | Liu JoyEVP and Chief Legal Officer · O | ▼ Sale | 828 | $439.91 | $364K | -4% | plan |
| May 29, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 1,974 | $450 | $888K | -8% | plan |
| May 4, 2026 | Bhatia Sangeeta N.D | ▼ Sale | 318 | $423.73 | $135K | -6.1% | plan |
| May 1, 2026 | Upadhyay SuketuD | ▽ Sale to issuer | 796 | — | — | -33.8% | — |
| May 1, 2026 | Thornberry NancyD | ▽ Sale to issuer | 398 | — | — | -15.9% | — |
| May 1, 2026 | Schneider JenniferD | ▽ Sale to issuer | 796 | — | — | -36.3% | — |
| May 1, 2026 | MCKENZIE DIANAD | ▽ Sale to issuer | 796 | — | — | -25.1% | — |
| May 1, 2026 | Liu JoyEVP and Chief Legal Officer · O | ▼ Sale | 1,104 | $425.02 | $469K | -5.1% | plan |
| Apr 1, 2026 | Liu JoyEVP and Chief Legal Officer · O | ▼ Sale | 978 | $449.17 | $439K | -4.3% | plan |
| Mar 27, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 2,329 | $450.95 | $1.1M | -6.6% | plan |
| Mar 13, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 2,329 | $481.79 | $1.1M | -6.2% | plan |
| Mar 11, 2026 | McKechnie DuncanEVP, Chief Commercial Officer · O | ▼ Sale | 2,633 | $498.42 | $1.3M | -17.4% | plan |
| Mar 4, 2026 | McKechnie DuncanEVP, Chief Commercial Officer · O | ▼ Sale | 2,437 | $475.3 | $1.2M | -13.9% | plan |
| Mar 2, 2026 | Liu JoyEVP and Chief Legal Officer · O | ▼ Sale | 892 | $495.96 | $442K | -3.8% | plan |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President · O·D | ▼ Sale | 40,000 | $493.47 | $19.7M | -28.9% | plan · 13 tranches |
| Feb 27, 2026 | Bozic CarmenEVP and CMO · O | ▼ Sale | 2,329 | $480.31 | $1.1M | -5.8% | plan |
| Feb 26, 2026 | Ambrose KristenSVP & Chief Accounting Officer · O | ▼ Sale | 357 | $483.36 | $173K | -5.1% | plan |
| Feb 25, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 260 | $486.35 | $126K | -0.6% | plan |
| Feb 25, 2026 | Sachdev AmitEVP Chief Patient & Ext Af Off · O | ▼ Sale | 1,846 | $486.35 | $898K | -3.2% | plan |
| Feb 25, 2026 | McKechnie DuncanEVP, Chief Commercial Officer · O | ▼ Sale | 4,910 | $487.65 | $2.4M | -21.9% | plan · 2 tranches |
| Feb 25, 2026 | Bunnage Mark E.EVP, Chief Scientific Officer · O | ▼ Sale | 620 | $486.35 | $302K | -7.8% | plan |
| Feb 25, 2026 | Biller JonathanEVP and Chief Legal Officer · O | ▼ Sale | 945 | $486.35 | $460K | -6.5% | plan |
| Feb 25, 2026 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · O | ▼ Sale | 668 | $486.35 | $325K | -3.5% | plan |
| Feb 25, 2026 | Ambrose KristenSVP & Chief Accounting Officer · O | ▼ Sale | 223 | $486.35 | $108K | -3.1% | plan |
| Feb 19, 2026 | Sachdev AmitEVP Chief Patient & Ext Af Off · O | ▼ Sale | 58,613 | $468.83 | $27.5M | -49.9% | plan · 8 tranches |
| Feb 18, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 977 | $483.52 | $472K | -2% | plan · 2 tranches |
| Feb 18, 2026 | Bunnage Mark E.EVP, Chief Scientific Officer · O | ▼ Sale | 3,619 | $484.31 | $1.8M | -29.9% | plan · 2 tranches |
| Feb 18, 2026 | Biller JonathanEVP and Chief Legal Officer · O | ▼ Sale | 3,720 | $484.18 | $1.8M | -19.1% | plan · 2 tranches |
| Feb 18, 2026 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · O | ▼ Sale | 2,848 | $484.93 | $1.4M | -12.1% | plan · 2 tranches |
| Feb 18, 2026 | Ambrose KristenSVP & Chief Accounting Officer · O | ▼ Sale | 2,195 | $484.87 | $1.1M | -22.1% | plan · 2 tranches |
| Feb 13, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 1,500 | $499.99 | $750K | -3.1% | plan |
| Feb 13, 2026 | Biller JonathanEVP and Chief Legal Officer · O | ▼ Sale | 988 | $499 | $493K | -5.5% | plan |
| Feb 13, 2026 | Bhatia Sangeeta N.D | ▼ Sale | 266 | $500 | $133K | -5.8% | plan |
| Feb 11, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 466 | $460.43 | $215K | -0.9% | plan |
| Feb 11, 2026 | Bunnage Mark E.EVP, Chief Scientific Officer · O | ▼ Sale | 2,021 | $460.43 | $931K | -13.5% | plan |
| Feb 11, 2026 | Biller JonathanEVP and Chief Legal Officer · O | ▼ Sale | 1,925 | $460.43 | $886K | -8.5% | plan |
| Feb 11, 2026 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off. · O | ▼ Sale | 1,751 | $460.43 | $806K | -7.4% | plan |
| Feb 11, 2026 | Ambrose KristenSVP & Chief Accounting Officer · O | ▼ Sale | 1,376 | $460.43 | $634K | -12% | plan |
| Jan 7, 2026 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 4,500 | $474.99 | $2.1M | -9.6% | plan |
| Jan 6, 2026 | WAGNER CHARLES F JREVP, CO & FO · O | ▼ Sale | 9,532 | $461 | $4.4M | -20.2% | plan |
| Dec 3, 2025 | WAGNER CHARLES F JREVP, CO & FO · O | ▼ Sale | 14,000 | $456 | $6.4M | -27.1% | plan · 2 tranches |
| Dec 3, 2025 | Tatsis OuraniaEVP, Chief Reg. & Quality Off. · O | ▼ Sale | 4,500 | $449.99 | $2.0M | -8.8% | plan |
| Dec 3, 2025 | LEIDEN JEFFREY MExecutive Chairman · O·D | ▼ Sale | 63,781 | $449.2 | $28.7M | -72.6% | plan · 12 tranches |
Every $VRTX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Vertex Pharmaceuticals Inc / Ma filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $VRTX feed.